Overview
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
Eligibility
Inclusion Criteria:
- Patient aged 18 or over,
- Patient presenting an invasive tumor pathology (proven or suspected). The location and / or stage of which are defined for each cohort through an amendment to the protocol,
- Patient treated with immune-modulators or other treatments likely to modify immunological parameters,
- Suspicion of immune mediated response or toxicities (assessed by the immunologists),
- Peripheral venous capital usable and compatible with the realization of 2 venous accesses for lymphapheresis and absence of cardiovascular problem (heart failure, arrhythmia ...), per investigator assessement,
- Total circulating lymphocytes> 1000 / mm3,
- Availability of DNA and RNA from the tumor,
- Information to the patient and signature of informed consent or his legal representative,
- Affiliated with a social security scheme or such a scheme.
Exclusion Criteria:
- Inability to undergo study follow-up for geographical, social or psychological reasons,
- Infection with HIV or hepatitis B or C viruses,
- Patients on high dose corticosteroid treatment (> 1 mg / kg continuously),
- Any concomitant serious illness that may interfere with participation in the study or significantly affect the results of the study (pulmonary, heart or liver disease),
- Contraindication to performing lymphapheresis (coagulation disorder, cardiovascular problems, venous access, hypocalcemia, psychological inability to undergo extracorporeal circulation, cachexia, etc.),
- Pregnant patient or of childbearing age without effective contraception,
- Persons deprived of their liberty, under guardianship or legal protection.